Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice

EXCLI Journal

Volumn 11, Issue , 2012, Pages 45-58

  Abdel Salam, Omar M E ^a   El Shamarka, Marawa El Sayed ^a   Salem, Neveen A ^a   Gaafar, Alaa El Din M ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Cannabis sativa extract; Catalepsy; Haloperidol; Mice

Indexed keywords

CANNABIS; DRONABINOL; GLUCOSE; GLUTATHIONE; MALONALDEHYDE; NITRATE; NITRIC OXIDE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; LIVER LEVEL; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; TREATMENT DURATION;

EID: 84867604234     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Ashton CH. Pharmacology and effects of cannabis: A brief review. Br J Psychiat 2001;178:101-6.
2. Basavarajappa BS, Nixon RA, Arancio O. Endocannabinoid system: emerging role from neurodevelopment to neurodegenera-tion. Mini Rev Med Chem 2009;9:448-62.
3. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C et al. Modulation of mediotemporal and ventrostriatal function in humans by Del-ta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66:442-51.
4. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-66.
5. Buccellato E, Carretta D, Utan A, Cavina C, Speroni E, Grassi G et al. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis. J Ethnopharmacol 2011;133:1033-8.
6. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antago-nist. Br J Pharmacol 2010;159:129-41.
7. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004;24:4393-400.
8. Croxford JL. Therapeutic potential of can-nabinoids in CNS disease. CNS Drugs 2003;17:179-202.
9. DeLong GT, Wolf CE, Poklis A, Lichtman AH. Pharmacological evaluation of the nat-ural constituent of Cannabis sativa, canna-bichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug Alcohol De-pend 2010;112:126-33.
10. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
11. Fernandez-Espejo E, Caraballo I, Rodri-guez de Fonseca F, Ferrer B, El Banoua F, Flores JA et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 2004;29:1134-42.
12. Ferri S, Costa G, Murari G, Panico AM, Rapisarda E, Speroni E et al. Investigations on behavioral effects of an extract of Can-nabis sativa L. in the rat. Psychopharma-cology 1981;75:144-7.
13. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. NSArch Pharma-col 2010;381:563-72.
14. Friedman E, Hanin I, Gershon S. Effect of tetrahydrocannabinols on 3H-acetylcholine biosynthesis in various rat brain slices. J Pharmacol Exp Ther 1976;196:339-45.
15. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R et al. Distinct effects of {delta}9-tetrahydro-cannabinol and cannabidiol on neural acti-vation during emotional processing. Arch Gen Psychiatry 2009;66:95-105.
16. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S et al. Modulation of effective connectivity during emotional processing by Delta 9-tetra-hydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010;13:421-32.
17. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constitu-ent of hashish. J Am Chem Soc 1964;86: 1646-7.
18. Gerra G, Zaimovic A, Gerra ML, Cicco-cioppo R, Cippitelli A, Serpelloni G et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010;5:46-52.
19. Gessa GL, Mascia MS, Casu MA, Carta G. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A. Eur J Pharmacol 1997;327:R1-R2.
20. Gilbert GL, Kim HJ, Waataja JJ, Thayer SA. Δ9-Tetrahydrocannabinol protects hip-pocampal neurons from excitotoxicity. Brain Res 2007;1128:61-9.
21. Gutteridge JMC. Lipid peroxidation and antioxidants as biomarkers of tissue dam-age. Clin Chem 1995;41:1819-28.
22. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydro-cannabinol are neuroprotective antioxi-dants. Proc Natl Acad Sci USA 1998;95: 8268-73.
23. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000;899:274-82.
24. Harvey DJ, Martin BR, Paton WDM. In vivo metabolism of cannabinol by the mouse and rat and a comparison with the metabolism of Δ1-tetrahydrocannabinol and cannabidiol. Biol Mass Spectrom 1977;4: 364-70.
25. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K et al. Cannabidiol potentiates pharmacological effects of Del-ta(9)-tetrahydrocannabinol via CB(1) recep-tor-dependent mechanism. Brain Res 2008; 1188:157-64.
26. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and canna-binoids 2005-2009. Cannabinoids 2010; 5(special issue):1-21.
27. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liabil-ity. Psychopharmacology 1995;120:128-33.
28. Imaki J, Mae Y, Shimizu S, Ohno Y. Ther-apeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced ex-trapyramidal motor disorders. Neurosci Lett 2009;454:143-7.
29. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a prom-ising drug for neurodegenerative disorders? CNS Neurosci Ther 2009;15:65-75.
30. Jibson MD, Tandon R. New atypical anti-psychotic medications. J Psychiatr Res 1998;32:215-28.
31. Karniol G, Carlini EA. Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmaco-logia 1973;33:53-70.
32. Kataoka Y, Ohta H, Fujiwara M, Oishi R, Ueki S. Noradrenergic involvement in cata-lepsy induced by Δ9-tetrahydrocannabinol. Neuropharmacology 1987;26:55-60.
33. Kinoshita H, Hasegawa T, Katsumata Y, Kameyama T, Yamamoto I, Nabeshima T. Effect of dizocilpine (MK-801) on the cata-lepsy induced by Δ9-tetrahydrocannabinol in mice. J Neural Transm [Gen Sect] 1994; 95:137-43.
34. Kleijn J, Cremers TI, Hofland CM, Wester-ink BH. CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex. Neurosci Res 2011;70:334-7.
35. Lakhan SE, Rowland M. Whole plant can-nabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurology 2009;9:59.
36. Ligresti A, Moriello AS, Starowicz K, Ma-tias I, Pisanti S, De Petrocellis L et al. Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318:1375-87.
37. Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T. A behav-ioural comparison of acute and chronic Del-ta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsycho-pharmacol 2010;13:861-76.
38. Marchese G, Casti P, Ruiu S, Saba PL, Sanna A, Casu GL et al. Haloperidol, but not clozapine, produces dramatic catalepsy in D9-THC-treated rats: possible clinical implications. Br J Pharmacol 2003;140: 520-6.
39. Moratalla R, Xu M, Tonegawa S, Graybiel AM. Cellular responses to psychomotor stimulant and neuroleptic drugs are abnor-mal in mice lacking the D1 dopamine re-ceptor. Proc Natl Acad Sci USA 1996;93: 14928-33.
40. Moshage H, Kok B, Huizenga JR. Nitrite and nitrate determination in plasma: A crit-ical evaluation. Clin Chem 1995;41:892-6.
41. Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabis in movement disor-ders. Forsch Komplementarmed 1999;6 (Suppl 3):23-7.
42. Natesan S, Reckless GE, Nobrega JN et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsy-chopharmacology 2006;31:1854-63.
43. Pertwee RG. The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br J Pharmac 1972;46: 753-63.
44. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005;168:1-51.
45. Pertwee RG. The diverse CB1 and CB2 re-ceptor pharmacology of three plant canna-binoids: delta9-tetrahydrocannabinol, can-nabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
46. Pertwee RG, Greentree SG. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flu-razepam or chlordiazepoxide. Neurophar-macology 1998;27:485-91.
47. Pertwee RG, Ross RA. Cannabinoid recep-tors and their ligands. Prostaglandins Leu-kot Essent Fatty Acids 2002;66:101-21.
48. Polydoro M, Schröder N, Lima MN, Calda-na F, Laranja DC, Bromberg E et al. Haloperidol-and clozapine-induced oxida-tive stress in the rat brain. Pharmacol Bio-chem Behav 2004;78:751-6.
49. Prinssen EP, Colpaert FC, Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced cata-lepsy. Eur J Pharmacol 2002;453:217-21.
50. Revuelta AV, Moroni F, Cheney DL, Costa E. Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex. NS Arch Pharmacol 1978;304:107-10.
51. Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM. Psychomotor performance in relation to acute oral admin-istration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci 2009;259:284-92.
52. Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of es-tradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver mi-crosomes. Steroids 1994;59:383-8.
53. Russo E, Guy GW. A tale of two canna-binoids: The therapeutic rationale for com-bining tetrahydrocannabinol and cannabidi-ol. Medical Hypotheses 2006;66:234-46.
54. Russo EB, McPartland JM. Cannabis is more than simply D9-tetrahydrocannabinol. Psychopharmacology 2003;165:431-2.
55. Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K et al. Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by de-creased 5-HT neurotransmission in the nu-cleus accumbens due to the action of glu-tamate-containing neurons. Neuroscience 2008;151:320-8.
56. Sastre-Garriga J, Vila C, Clissold S, Mon-talban X. THC and CBD oromucosal spray (Sativex A®) in the management of spastic-ity associated with multiple sclerosis. Ex-pert Rev Neurother 2011;11:627-37.
57. Schrag A, Schelosky L, Scholz U, Poewe W. Reduction of Parkinsonian signs in pa-tients with Parkinson's disease by dopamin-ergic versus anticholinergic single-dose challenges. Mov Disord 1999;14:252-5.
58. Tarsy D. Initial treatment of Parkinson's disease. Curr Treat Options Neurol 2006;8: 224-35.
59. Taura F, Sirikantaramas S, Shoyama Y, Shoyama Y, Morimoto S. Phytocanna-binoids in Cannabis sativa: recent studies on biosynthetic enzymes. Chem Biodiv 2007;4:1649-63.
60. Thakur GA, Duclos RI, Makriyannis A. Natural cannabinoids: templates for drug discovery. Life Sci 2005;78:454-66.
61. Trevitt J, Vallance C, Harris A, Goode T. Adenosine antagonists reverse the catalep-tic effects of haloperidol: implications for the treatment of Parkinson's disease. Phar-macol Biochem Behav 2009;92:521-7.
62. Trinder P. Determination of glucose in blood using glucose oxidase with an alter-native oxygen acceptor. Ann Clin Biochem 1969;6:24-5.
63. Tripathi HL, Vocci FJ, Brase DA, Dewey WL. Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain. Alcohol Drug Res 1987;7:525-32.
64. Turner JC, Mahlberg PG. Separation of ac-id and neutral cannabinoids in Cannabis sativa L. using HPLC. In: Agurell S, Dew-ey WL, Willete RE (eds.): The canna-binoids: chemical, pharmacologic and ther-apeutic aspects (pp 79-88). Orlando, Fla: Academic Press Inc, 1984.
65. van der Stelt M, Veldhuis WB, Bär PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta 9-tetrahydro-cannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-9.
66. van Vliet SA, Vanwersch RA, Jongsma MJ, Olivier B, Philippens IH. Therapeutic ef-fects of Delta 9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsy-chopharmacol 2008;18:383-9.
67. Vara D, Salazar M, Olea-Herrero N, Guz-mán M, Velasco G, Díaz-Laviada I. Anti-tumoral action of cannabinoids on hepato-cellular carcinoma: role of AMPK-depend-ent activation of autophagy. Cell Death Dif-fer 2011;18:1099-111.
68. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH. Δ9-tetra-hydrocannbinol accounts for the antino-ciceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 2005;314:329-37.
69. Venderová K, Růzicka E, Vorísek V, Visnovský P. Survey on cannabis use in Parkinson's disease: subjective improve-ment of motor symptoms. Mov Disord 2004;19:1102-6.
70. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychia-try Res 2001;107:173-7.
71. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D2 receptor occu-pancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-41.
72. Watanabe K, Yamaori S, Funahashi T, Ki-mura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tet-rahydrocannabinols and cannabinol by hu-man hepatic microsomes. Life Sci 2007;80: 1415-9.
73. Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S et al. Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Phar-macol 2003;55:1687-94.
74. Yamamoto I, Watanabe K, Matsunaga T, Kimura T, Funahashi T, Yoshimura H. Pharmacology and toxicology of major constituents of marijuana-On the metabolic activation of cannabinoids and its mecha-nism. J Toxicol 2003;22:577-89.
75. Zajicek JP, Apostu VI. Role of canna-binoids in multiple sclerosis. CNS Drugs 2011;25:187-201.
76. Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SRL. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol 2010;159:122-8.